Keyphrases
Colombia
100%
Liraglutide
100%
Type 2 Diabetes Mellitus Patients
100%
Dulaglutide
100%
Glargine
100%
Cost-effectiveness
100%
Quality-adjusted Life Years
55%
Incremental Cost-effectiveness Ratio
44%
Diabetic Vascular Complications
22%
Increasing Population
11%
Colombians
11%
Local Studies
11%
Comparative Cost-effectiveness
11%
Probabilistic Sensitivity Analysis
11%
Drug Offers
11%
Type 1 Diabetes Mellitus (T1DM)
11%
Payer Perspective
11%
GDP per Capita
11%
Markov Model
11%
Diabetes Management
11%
Glucometry
11%
Local Database
11%
Discount Rate
11%
Peso
11%
Nondaily
11%
Sensibility Analysis
11%
Transition Probability
11%
Third-party Payers
11%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Cost-Effectiveness Analysis
100%
Dulaglutide
100%
Liraglutide
100%
Health Care Cost
77%
Quality Adjusted Life Year
55%
Base
11%
Diabetes
11%
Circannual Rhythm
11%
Fenfluramine
11%
Diabetes Mellitus
11%
Head
11%
INIS
comparative evaluations
100%
colombia
100%
patients
100%
cost
100%
diabetes mellitus
100%
drugs
13%
populations
6%
values
6%
increasing
6%
probabilistic estimation
6%
weight
6%
probability
6%
sensitivity analysis
6%
injection
6%
gross domestic product
6%
markov process
6%
discount rate
6%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Dulaglutide
100%
Maturity Onset Diabetes of the Young
100%
Base
11%
Diabetes Mellitus
11%
Fenfluramine
11%